Physician profile
Ray M Freeman
NPI 1962504514
$2,139.71
in general payments reported to CMS, 2019-2025
16 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.31 · 2022: $665 · 2023: $494 · 2024: $358 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.96 | 2022-2025 | |
| Biotissue Holdings INC. | $261.88 | 2022-2023 | |
| Alcon Vision LLC | $207.47 | 2021-2025 | Tryptyr, Rocklatan, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $147.62 | 2022-2025 | Eylea Hd |
| Genentech USA, INC. | $146.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $104.20 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $96.76 | 2022-2023 | Cequa |
| Amgen INC. | $64.26 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $37.82 | 2025 | Xdemvy |
| Harrow Eye, LLC | $29.79 | 2024 | Vevye |
| Bausch & Lomb Americas INC. | $24.12 | 2024 | Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $23.81 | 2022 | |
| Ocular Therapeutix, INC. | $20.72 | 2022 | |
| Glaukos Corporation | $18.77 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $17.09 | 2023 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $16.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.